Concepedia

Peter Olson

PO

Statistics

Publications

64

Citations

13.6K

H-Index

38

Active since

1997

Affiliations

Mirati Therapeutics (United States)(Current)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

University of California, San Francisco

Pfizer (United States)

Peter Olson is an author at Mirati Therapeutics (United States) specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

1997–2025

64

Publications

64

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Eric A. Collisson, Anguraj Sadanandam, Peter Olson et al. · Nature Medicine · 2011 · 2K citations · Full text

, , +10

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

Neta Erez, Morgan Truitt, Peter Olson et al. · Cancer Cell · 2010 · 1.5K citations · Full text

, , +17

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

, , +17

Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle

Weimin He, Yaacov Barak, Andrea L. Hevener et al. · Proceedings of the National Academy of Sciences · 2003 · 964 citations · Full text

, , +17

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 708 citations · Full text

, , +14

1–5 of 64